leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience gains after announcing cannabinoid R&D project is underway

This project is testing for a variety of potential performance-enhancing variations of the company's DehydraTECH delivery technology

Lexaria tables
DehydraTECH can be applied to foods, beverages, tablets and capsules

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) climbed Wednesday after announcing that its largest-ever cannabinoid research and development project is underway.

This project will test for a variety of potential performance-enhancing variations of the company's DehydraTECH delivery technology.

Shares of Lexaria advanced C$0.03 to C$1.65 in Wednesday’s Canadian trading. They traded at US$1.21 on the OTC Markets.

READ: Lexaria Bioscience cites FDA statement on nicotine replacement therapy to help smokers quit

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

Lexaria’s approach can be applied to foods, beverages, oral suspensions, tablets and capsules.

In addition, the R&D program will for the first time ever evaluate DehydraTECH in combination with nanotech emulsion formulas evaluated last year, according to Lexaria.

Comparable studies

The program is made up of 11 separate animal studies, each of which is comparable in scope to individual animal studies conducted in 2018.

Separately, the Kelowna, British Columbia, company said it has terminated a license agreement between Lexaria CanPharm ULC and NeutiSci International Inc (CVE:NU) (OTCMKTS:NRXCF), announced in February 2018.

Last month, Lexaria cited a Food and Drug Administration statement on the development of safe and effective nicotine replacement therapies to help smokers quit cigarettes.

In January, a unit of Lexaria entered into a definitive agreement with Altria Group Inc (NYSE:MO) to fund research on regulatory compliant, oral forms of nicotine delivery.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Quick facts: Lexaria Bioscience Corp.

Price: 0.345 CAD

CSE:LXX
Market: CSE
Market Cap: $30.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience signs R&D agreement with British American Tobacco

Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries. Bunka telling...

2 weeks, 4 days ago

2 min read